# **ACORN CAPITAL INVESTMENT FUND LTD**

**INVESTOR UPDATE – SEPTEMBER 2022** 





#### DISCLAIMER AND IMPORTANT INFORMATION

#### IMPORTANT NOTICE AND DISCLAIMER

This presentation has been prepared by Acorn Capital Investment Fund Limited ACN 167 595 897 (ACQ). The information in this presentation is only intended for Australian residents. The purpose of this presentation is to provide information only and the contents of the presentation does not purport to provide investment advice. We strongly suggest that investors consult a financial adviser prior to making any investment decision. The presentation does not take into account the investment objectives, financial situation or particular needs of any person and should not be used as the basis for making investment, financial or other decisions. The information is selective and may not be complete or accurate for your particular purposes and should not be construed as a recommendation to invest in any particular investment or security, or fund/company offered by ACQ or Acorn Capital Limited (Acorn Capital).

The information provided in the presentation is given in good faith and is believed to be accurate at the time of compilation. Neither Acorn Capital, ACQ, nor its directors or employees make any representation or warranty as to the accuracy, reliability, timeliness or completeness of the information.

To the extent permissible by law, Acorn Capital, ACQ and its respective officers, employees agents and advisers give no warranty, representation or guarantee as to the accuracy, completeness or reliability of the information contained in this presentation. Further neither ACQ nor Acorn Capital, or its respective officers, employees, agents and advisors accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of or in connection with the information contained in this presentation. Any recipients of this presentation should independently satisfy themselves as to the accuracy of all information contained herein.

#### LONSEC RESEARCH

The rating issued 09/2022 is published by Lonsec Research Pty Ltd ABN 11 151 658 561 AFSL 421 445 (Lonsec). Ratings are general advice only, and have been prepared without taking account of your objectives, financial situation or needs. Consider your personal circumstances, read the product disclosure statement and seek independent financial advice before investing. The rating is not a recommendation to purchase, sell or hold any product. Past performance information is not indicative of future performance. Ratings are subject to change without notice and Lonsec assumes no obligation to update. Lonsec uses objective criteria and receives a fee from the Fund Manager. Visit lonsec.com.au for ratings information and to access the full report. © 2022 Lonsec. All rights reserved.



#### **KEY MESSAGES**

Challenging markets continued with high volatility during the September 2022 quarter – ACQ was up 1.2%, the ASX Small Caps were down 0.5%

ACQ announced a 4.25c/share fully franked dividend, payable in November 2022

Lonsec "Recommended" rating retained 1

Market conditions are providing relatively attractive conditions for deploying capital into microcaps

Refer page 2 for Lonsec disclaimer



## **STRATEGY**

ACQ investment strategy has demonstrated an ability to deliver positive investment outcomes 1

#### 1. DIVIDEND INCOME

#### 2. CAPITAL GROWTH 3. DIVERSIFICATION <sup>2</sup>







<sup>1.</sup> As at 30 June 2022 the ACQ gross portfolio return has outperformed the S&P/Small Ordinaries Accumulation Index by 3.2% p.a. since ACQ listed on the ASX on 1 May 2014. Past performance is not a reliable indicator of future performance

<sup>2.</sup> Acorn Capital believes that the ACQ investment strategy should provide diversification benefits to an already diversified investment portfolio

# **SECTOR OBSERVATIONS**





#### **DIVERSIFICATION IN MICROCAPS IS PARAMOUNT**


It is not about picking a single winning sector - the key is the best stocks in each sector

CALENDAR YEAR MICROCAP SECTOR RETURNS – RANKED HIGHEST TO LOWEST								
2014	2015	2016	2017	2018	2019	2020	2021	CYTD-22
26.7% (return)	69.0%	49.6%	41.8%	7.7%	51.5%	72.5%	37.9%	4.3%
AREITs (sector)	Staples	Indust – Capital	AREITs	Telco	IT	Resources	Resources	Energy
22.1%	45.3%	48.4%	35.8%	5.5%	39.8%	45.2%	32.5%	-5.2%
Staples	Telco	Resources	Resources	AREITs	Healthcare	IT	Energy	Indust -ex Capital
17.2%	36.1%	20.8%	33.5%	-0.4%	35.1%	30.5%	30.8%	-12.8%
Telco	IT	Indust -ex Capital	Indust - Capital	Staples	Discretionary	Discretionary	Indust - Capital	Indust - Capital
16.3%	21.2%	20.7%	30.1%	-6.3%	33.2%	24.5%	29.8%	-14.6%
Financials	Healthcare	Telco	Staples	Indust -ex Capital	Financials	Microcap Index	Indust -ex Capital	Staples
12.9%	21.0%	19.2%	26.5%	-7.4%	26.5%	13.2%	28.1%	-17.2%
Discretionary	AREITs	AREITs	Financials	Financials	Indust - Capital	Healthcare	Telco	Resources
2.6%	16.4%	15.7%	20.4%	-9.7%	24.5%	10.2%	26.3%	-21.3%
IT	Discretionary	Microcap Index	Microcap Index	Energy	Microcap Index	Telco	Discretionary	Microcap Index
-7.9%	10.5%	15.0%	17.5%	-12.8%	16.6%	7.3%	25.3%	-22.7%
Microcap Index	Financials	Energy	IT	Discretionary	Staples	AREITs	AREITs	AREITs
-11.2%	10.4%	11.8%	11.2%	-14.2%	16.4%	5.3%	23.6%	-27.3%
Healthcare	Microcap Index	Healthcare	Indust -ex Capital	Microcap Index	Indust -ex Capital	Financials	Microcap Index	Financials
-14.5%	5.1%	7.2%	9.1%	-14.2%	16.0%	4.1%	15.5%	-29.5%
Indust -ex Capital	Indust -ex Capital	Financials	Telco	Healthcare	Resources	Energy	Financials	Healthcare
-25.6%	-3.4%	1.5%	5.2%	-15.0%	14.1%	0.8%	14.9%	-30.5%
Indust - Capital	Resources	Discretionary	Discretionary	Indust - Capital	AREITs	Indust - Capital	Healthcare	IT
-28.4%	-20.8%	-9.1%	4.6%	-24.4%	-0.1%	-3.5%	-0.2%	-32.7%
Resources	Indust - Capital	Staples	Energy	IT	Telco	Indust -ex Capital	IT	Discretionary
-30.4%	-29.7%	-15.3%	0.7%	-26.3%	-4.1%	-5.2%	-2.0%	-33.7%
Energy	Energy	IT	Healthcare	Resources	Energy	Staples	Staples	Telco

 $Source: A corn\ Capital/SIRCA\ Microcap\ Index\ .\ Does\ not\ include\ Utilities\ or\ Materials\ ex-Resources\ as\ <2\%\ of\ universe$ 



## **CURRENT BEAR MARKET IN MICROCAPS**




#### Acorn Capital has observed 9 Microcap bear markets since 1974 1

	Median	Average
Bear market duration (months)	15	14.8
Max drawdown of bear market	-31.3%	-37.5%
Return in 12 months post max drawdown	38.6%	49.6% <sup>2</sup>

- 1. Observations/calculations based on monthly time series of returns for Acorn Capital/SIRCA Microcap Index
- 2. Excludes current (2022) bear market, hence 8 observations



# CURRENT MARKET PROVIDES ATTRACTIVE CONDITIONS TO DEPLOY LONG TERM CAPTIAL




# **STOCKS IN FOCUS**






#### INTERNATIONAL EDUCATION REBOUND

- At Dec 2019 Australia had 952k international students enrolled, with 510k new student commencing that year. Mainland Chinese students were 27% of the total.
- Commencements fell 44% to 284k in 2021.
- 117k commenced English courses (ELICOS) in 2019, with Chinese being 36% of all enrolled students.
  Total commencements fell by 75% to 29k in 2021.
- ELICOS leads student recovery growing 7.5% YoY in July, 22% ex-China growth.
- iCollege's Greenwich English is a ELICOS leader & has <1% China student exposure.</li>
- iCollege remained open as competitors closed in Covid, enrolments in Sep 2022 at 3,200 are 50% higher than the pre-Covid peak 1,922 in Dec-2019. 30% of ELICOS students transition to Greenwich diplomas/degrees.








#### AROA BIOSURGERY – DON'T HAVE A HERNIA!

- Aroa has been a long term top 10 position, originally held as an unlisted investment in 2016
- Aroa was negatively impacted by COVID-19 pandemic (delayed procedures)
- Fundamentals are very positive:
  - Revenue momentum FY23(f) c\$55m, EBITDA positive in FY24 and c\$90 -\$100m rev in FY25f
  - Multiple FDA approved devices in commercialisation (Ovitex, Myriad, Endoform)
  - Exciting pipeline of innovate devices (Symphony, LEAF)
  - Exceptional clinical evidence (Ovitex on its way to being to be a category leader in Hernia)
  - Strong balance sheet with optionality forecasting > \$40m cash on balance sheet end FY23
  - Undemanding valuation and beneficiary of falling USDNZD exchange rates
  - Customer demand not impacted by tighter economic conditions





1. SmartTRAK BiomedGPS data 2020; DRG Millennium Research data; Hernia Repair Devices, 2020, AROA management estimates; DRG Millennium Research, Breast Implants & Reconstructive devices, 2018. 2. SmartTRAK BiomedGPS data 2020. Aroa management estimates. 3. DRG Millennium Research data; Hernia Repair Devices, 2020. DRG Millennium Research, Breast Implants & Reconstructive devices, 2018.



## COOPER ENERGY – DOMESTIC GAS SUPPLY


Cooper Energy is an ASX-listed energy company which generates revenue from the discovery, commercialisation and sale of gas to southeast Australia and low-cost Cooper Basin oil production

#### The opportunity:

- Supply shortfall for domestic gas in southeastern Australia
- Volatile energy markets
- Increased focus on cleaner fuels in the energy mix

#### Cooper Energy's advantage:

- Growing production from two major gas operations in Victoria
- First major gas producer in Australia to be net-zero (Scope 1, 2 and controllable 3 emissions)
- Strong development pipeline



1 Source: Cooper Energy analysis of January 2022 ACCC Gas Inquiry Report | 2Supply includes Cooper Basin, Otway Basin and Gippsland Basin. Demand includes VIC, NSW, SA, ACT and TAS. | 3 Source: Bloomberg & Australian Energy Market Operator's (AEMO). Data presented up to 18 June 2022. | 4 Source: ACCC as at 16 August 2022; LNG n

# PORTFOLIO & PERFORMANCE






# **KEY FACTS - 30 SEPTEMBER 2022**

Pre-tax NTA	1.1644	Performance - since inception <sup>5,7</sup>	8.7
Post-tax NTA <sup>1</sup>	1.1459	Benchmark - since inception <sup>6,7</sup>	5.4
ACQ share price	\$1.09	Investment Split CASH, 5.4%	
Ordinary Dividends <sup>2</sup>	8.50c		UNLISTED, 25.8%
Implied cash dividend yield <sup>3</sup>	7.6%		
Franking on dividends <sup>4</sup>	100%		
Shares Outstanding	86.1m	LISTED, 68.8%	
Market Capitalisation	\$93.8m		
Number of stocks	81	Lonsec Rating <sup>8</sup>	
		Lonsec Research	

- Post-tax NTA = before taxes on unrealised gains
- 2. Fully franked dividend and includes dividend of 4.25c payable in Nov 2022
- 3. Based on share price as at 30 September 2022
- 4. Dividends paid are estimated to be franked at a rate of 30% (subject to availability of franking credits)
- 5. Calculated as the movement in NTA before tax, post management fees, performance fees and operating costs. Includes dividends paid and payable but has not been grossed-up for franking credits received by shareholders. All figures are unaudited, and unlisted valuations are performed by Acorn Capital in accordance with ACQ Board approved policies.
- 5. S&P/Small Ordinaries Accumulation Index
- 7. Inception is the date ACQ listed on the ASX which was 1 May 2014
- 8. Lonsec Research refer to disclaimer on Page 2



# **GROWTH OF \$10K**



#### **ACQ Dividend Policy**

"Acorn Capital Investment Fund Limited intends to pay annual dividends targeting at least 5% of closing post-tax NTA for each financial year, franked to the highest extent possible and without the Company incurring a liability. Where the Company accumulates franking credits that the Board determines are in excess to its requirements it is the intent to distribute those excess credits by way of special dividends. This is subject to the Company having sufficient profit and cash flow to make such payments."


- 1. ASX listing date 1 May 2014
- 2. Total shareholder return assuming dividends reinvested, includes special dividends



# PORTFOLIO OVERVIEW<sup>1</sup>

#### **TOP 10 INVESTMENTS**

	Company	Weight %
1	Moula Money <sup>2</sup>	3.9
2	Marketplacer <sup>2</sup>	3.6
3	Splend Holdings <sup>2</sup>	3.5
4	Icollege	3.0
5	Aroa Biosurgery	2.7
6	Australian Rare Earths	2.7
7	Cooper Energy	2.5
8	Syrah Resources	2.4
9	MX51 Group <sup>2</sup>	2.2
10	Calix	2.1
	Total	28.6



Utilities

Cash

<sup>1.</sup> Acorn Capital, as at 30 September 2022

<sup>2.</sup> Unlisted Investment



# **PERFORMANCE**

Portfolio Return for Periods to 30 Sept 2022	3 months %	1 year %	3 years % p.a.	5 years % p.a.	Since inception % p.a. <sup>3</sup>
ACQ (Post Fees & Op Costs) <sup>1</sup>	1.2	-24.6	6.0	10.4	8.7
S&P/ASX Small Ords Acc. Index <sup>4</sup>	-0.5	-22.6	-0.8	4.1	5.4
Value add	+1.7	-2.1	+6.8	+6.3	+3.4
Alternate market indices					
Acorn Capital / SIRCA Microcap Acc. Index <sup>2</sup>	7.9	-16.9	7.7	8.3	7.8
S&P/Emerging Companies Index <sup>4</sup>	4.8	-18.2	10.1	10.8	10.0


<sup>1.</sup> Portfolio performance is unaudited and calculated as the movement in NTA before tax effects, which is post all management fees, performance fees and operating costs. Performance includes dividends paid and payable but has not been grossed up for franking credits received by shareholders. All figures include unlisted valuations that are performed by Acorn Capital in accordance with ACQ Board approved policies

<sup>2.</sup> Acorn Capital / SIRCA Microcap Accumulation Index data is verified 3 months in arrears by SIRCA ('Securities Industry Research Centre of Asia-Pacific')

<sup>3.</sup> Inception is 1 May 2014


<sup>4.</sup> Source: Factset






#### **PROVEN STRATEGY**

- ACQ's investment strategy has outperformed its benchmark since inception
- Specialised investment process developed over 20 years and tested through market cycles



# ATTRACTIVE DIVIDEND YIELD

- 4.25 cents interim dividend announced – payable Nov 2022
- 8.50 cents in fully franked ordinary dividends paid in past 12 months
- Policy of paying a dividend of at least 5% of the 30 June Post-Tax NTA and distributing excess franking credits by way of special dividend



# UNIQUE PORTFOLIO & ATTRACTIVE RETURNS

- ACQ provides investors with a unique emerging company portfolio, that is difficult to replicate
- Risk managed through bottom-up stock selection and diversification of both industry and stage of development
- Through ACQ's investment activities retail investors in ACQ have access to institutional placements
- Acorn Capital continues to see attractive unlisted investments for deployment of ACQ capital



Туре	Listed Investment Company
Objective	To achieve after-fee returns in the long-term that are higher than the S&P/ASX small Ordinaries accumulation index
Benchmark	S&P/ASX Small Ordinaries Accumulation Index
Investment universe	Australian Listed Equities Unlisted investments Cash
Stock #	60 - 80
Liquidity	On market
Investment timeframe	3 - 5 years
Dividends	Targeted semi annually (May and Nov)
Market Cap	\$93.8m (30 September 2022)
Management fee	0.95%
Performance fee	20% of returns in excess of the benchmark

Sector limits	Stock: +/- 7.5% at purchase Benchmark: +/- 7.5%
Board	John Steven – Chair Judith Smith David Trude Robert Brown
Shorting	The fund is long only. The fund is not permitted to short sell securities.
Investment Manager	Acorn Capital Ltd

# **FURTHER INFORMATION**

Dan McAleer danmcaleer@acorncapital.com.au

Matthew Sheehan matthewsheehan @acorncapital.com.au

Robert Routley robertroutley@acorncapital.com.au

www.acqfund.com.au